248 related articles for article (PubMed ID: 26787236)
21. Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.
Horwitz S; Coiffier B; Foss F; Prince HM; Sokol L; Greenwood M; Caballero D; Morschhauser F; Pinter-Brown L; Iyer SP; Shustov A; Nichols J; Balser J; Balser B; Pro B
Ann Oncol; 2015 Apr; 26(4):774-779. PubMed ID: 25605745
[TBL] [Abstract][Full Text] [Related]
22. Ukraine Data on Prognostic Factors and Treatment Outcomes in Patients with Peripheral T-Cell Lymphomas.
Skrypets T; Novosad O; Pastushenko Y; Gorbach O; Kriachok I
Klin Onkol; 2019; 32(6):436-444. PubMed ID: 31842562
[TBL] [Abstract][Full Text] [Related]
23. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma.
Toledano MN; Desbordes P; Banjar A; Gardin I; Vera P; Ruminy P; Jardin F; Tilly H; Becker S
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):680-688. PubMed ID: 29344718
[TBL] [Abstract][Full Text] [Related]
24. Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report.
Tout M; Casasnovas O; Meignan M; Lamy T; Morschhauser F; Salles G; Gyan E; Haioun C; Mercier M; Feugier P; Boussetta S; Paintaud G; Ternant D; Cartron G
Blood; 2017 May; 129(19):2616-2623. PubMed ID: 28251914
[TBL] [Abstract][Full Text] [Related]
25. Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma.
Kanoun S; Rossi C; Berriolo-Riedinger A; Dygai-Cochet I; Cochet A; Humbert O; Toubeau M; Ferrant E; Brunotte F; Casasnovas RO
Eur J Nucl Med Mol Imaging; 2014 Sep; 41(9):1735-43. PubMed ID: 24811577
[TBL] [Abstract][Full Text] [Related]
26. Baseline total metabolic tumor volume combined with international peripheral T-cell lymphoma project may improve prognostic stratification for patients with peripheral T-cell lymphoma (PTCL).
Jiang C; Teng Y; Chen J; Wang Z; Zhou Z; Ding C; Xu J
EJNMMI Res; 2020 Sep; 10(1):110. PubMed ID: 32965554
[TBL] [Abstract][Full Text] [Related]
27. Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial.
Schmitz C; Rekowski J; Müller SP; Hertenstein B; Franzius C; Ganser A; Bengel FM; Kroschinsky F; Kotzerke J; La Rosée P; Freesmeyer M; Hoeffkes HG; Hertel A; Behringer D; Mesters R; Weckesser M; Mahlmann S; Haberkorn U; Martens U; Prange-Krex G; Brenner W; Giagounidis A; Moeller R; Runde V; Sandmann M; Hautzel H; Wilop S; Krohn T; Dürk H; Heike M; Alashkar F; Brinkmann M; Trenn G; Wacker D; Kreisel-Büstgens C; Bernhard H; Heil G; Larisch R; Kurch L; Jöckel KH; Hoelzer D; Klapper W; Boellaard R; Dührsen U; Hüttmann A
Hematol Oncol; 2020 Aug; 38(3):244-256. PubMed ID: 32067259
[TBL] [Abstract][Full Text] [Related]
28. Value of interim FDG PET/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma.
Moon SH; Lee AY; Kim WS; Kim SJ; Cho YS; Choe YS; Kim BT; Lee KH
Leuk Lymphoma; 2017 Jun; 58(6):1341-1348. PubMed ID: 27718766
[TBL] [Abstract][Full Text] [Related]
29. The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma.
Hong JY; Hong ME; Choi MK; Chang W; Do IG; Jo JS; Jung SH; Park S; Kim SJ; Ko YH; Kim WS
Anticancer Res; 2015 Apr; 35(4):2465-74. PubMed ID: 25862915
[TBL] [Abstract][Full Text] [Related]
30. [Prognostic value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in extensive-stage small cell lung cancer].
Ding CY; Guo Z; Li YY; Li TR
Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):828-834. PubMed ID: 29151289
[No Abstract] [Full Text] [Related]
31. Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma.
Cottereau AS; Hapdey S; Chartier L; Modzelewski R; Casasnovas O; Itti E; Tilly H; Vera P; Meignan MA; Becker S
J Nucl Med; 2017 Feb; 58(2):276-281. PubMed ID: 27754905
[TBL] [Abstract][Full Text] [Related]
32. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma.
Albano D; Bertoli M; Battistotti M; Rodella C; Statuto M; Giubbini R; Bertagna F
Ann Nucl Med; 2018 Oct; 32(8):532-541. PubMed ID: 29982990
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of metabolic parameters measured by
Chang H; Lee SJ; Lim J; Lee JS; Kim YJ; Lee WW
J Cancer Res Clin Oncol; 2019 May; 145(5):1361-1367. PubMed ID: 30900157
[TBL] [Abstract][Full Text] [Related]
35. Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma.
Cottereau AS; Lanic H; Mareschal S; Meignan M; Vera P; Tilly H; Jardin F; Becker S
Clin Cancer Res; 2016 Aug; 22(15):3801-9. PubMed ID: 26936916
[TBL] [Abstract][Full Text] [Related]
36. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
Wu LL; Liang JH; Wang L; Xu W; Ding CY
Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
[No Abstract] [Full Text] [Related]
38. The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores.
Huh SJ; Oh SY; Lee S; Lee JH; Kim SH; Lee GW; Kim SJ; Kim WS; Lee HS; Jo JC; Kim MJ; Kwon JH; Kim HJ
Int J Hematol; 2019 Oct; 110(4):438-446. PubMed ID: 31250282
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry.
Pedersen MB; Hamilton-Dutoit SJ; Bendix K; Møller MB; Nørgaard P; Johansen P; Ralfkiaer E; Brown Pde N; Hansen PB; Jensen BA; Madsen J; Schöllkopf C; d'Amore F
Hematol Oncol; 2015 Dec; 33(4):120-8. PubMed ID: 25052551
[TBL] [Abstract][Full Text] [Related]
40. Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy.
Kim YR; Kim JS; Kim SJ; Jung HA; Kim SJ; Kim WS; Lee HW; Eom HS; Jeong SH; Park JS; Cheong JW; Min YH
J Hematol Oncol; 2011 Aug; 4():34. PubMed ID: 21843362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
